An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02568943
- Locations
- 🇸🇪
Novartis Investigative Site, Umea, Sweden
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Phase 2
Terminated
- Conditions
- Alzheimers Disease
- Interventions
- Biological: CAD106 ImmunotherapyOther: Placebo to CAD106Drug: CNP520Other: Placebo to CNP520Other: Alum
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 480
- Registration Number
- NCT02565511
- Locations
- 🇺🇸
Banner Sun City Research Institute, Sun City, Arizona, United States
🇺🇸California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States
🇺🇸Advanced Clinical Research, Meridian, Idaho, United States
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT02565576
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients
Phase 4
Completed
- Conditions
- COPD
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 379
- Registration Number
- NCT02566031
- Locations
- 🇰🇷
Novartis Investigative Site, Ulsan, Korea, Republic of
Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT02566044
- Locations
- 🇩🇪
Novartis Investigative Site, Koeln, Germany
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 877
- Registration Number
- NCT02563067
- Locations
- 🇨🇳
Novartis Investigative Site, Taichung, Taiwan
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT02559622
- Locations
- 🇩🇪
Novartis Investigative Site, Ulm, Germany
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 894
- Registration Number
- NCT02555683
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
Phase 4
Completed
- Conditions
- Acute Heart Failure
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 887
- Registration Number
- NCT02554890
- Locations
- 🇺🇸
Novartis Investigative Site, Wausau, Wisconsin, United States
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2216
- Registration Number
- NCT02554786
- Locations
- 🇬🇧
Novartis Investigative Site, Wiltshire, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath